{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T23:48:48Z","timestamp":1782949728892,"version":"3.54.5"},"reference-count":90,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Pain associated with severe burn injury is one of the most intense and clinically challenging to manage, as the metabolic imbalances associated with the inflammation caused by the injury and treatment interventions (e.g., dressing changes and debridement, excision, and grafting) can further worsen the pain. In the pharmacologic management of a complex, hospitalized patient with burn injuries, opioid therapy remains an efficacious mainstay of treatment. However, the complex nature of pain, injury characteristics, and common demographics after burn injury place patients at high risk of opioid-related adverse events. Thus, guidelines recommend that decisions about choice of opioid be based on physiology, pharmacology, and physician experience, in addition to individualizing initial treatment with subsequent continual adjustments throughout care. Although substantial progress has been made in pain management strategies with utilization of nonopioid medications and nonpharmacologic adjuncts to opioid pharmacotherapy, there is still a need to evaluate new therapies, as an optimal regimen still lacks significant evidential support. Herein, we review the actions of opioids at the cellular level, contributing to both nociception and opioid-related adverse events. We also discuss the most recently approved intravenously administered opioid, oliceridine, developed utilizing biased ligand technology, including a summary of its clinical efficacy and safety in the management of severe acute pain. While oliceridine has been evaluated for the management of moderate-to-severe acute pain, the large phase 3 studies did not include patients with burn injuries. However, potential implications and future study direction for pain associated with burn injury are discussed.<\/jats:p>","DOI":"10.1093\/jbcr\/irad004","type":"journal-article","created":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T01:43:43Z","timestamp":1673660623000},"page":"524-534","source":"Crossref","is-referenced-by-count":14,"title":["State and Future Science of Opioids and Potential of Biased-ligand Technology in the Management of Acute Pain After Burn Injury"],"prefix":"10.1093","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1119-1901","authenticated-orcid":false,"given":"David M","family":"Hill","sequence":"first","affiliation":[{"name":"Clinical Pharmacist, Department of Pharmacy, Regional One Health , 877 Jefferson Avenue, Memphis, Tennessee 38103 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"DeBoer","sequence":"additional","affiliation":[{"name":"Trevena, Inc. , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,1,13]]},"reference":[{"key":"2023050213312215700_CIT0001","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1097\/BCR.0b013e31825adcb0","article-title":"Opioid-induced hyperalgesia and burn pain","volume":"33","author":"Holtman","year":"2012","journal-title":"J Burn Care Res"},{"key":"2023050213312215700_CIT0002","first-page":"11291152","article-title":"American Burn Association Guidelines on the Management of Acute Pain in the Adult Burn Patient: a review of the literature, a compilation of expert opinion and next steps","volume":"41","author":"Romanowski","year":"2020","journal-title":"J Burn Care Res"},{"key":"2023050213312215700_CIT0003","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.cps.2017.05.005","article-title":"Principles of burn pain management","volume":"44","author":"James","year":"2017","journal-title":"Clin Plast Surg"},{"key":"2023050213312215700_CIT0004","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-020-0145-5","article-title":"Burn injury","volume":"6","author":"Jeschke","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2023050213312215700_CIT0005","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.burns.2022.02.002","article-title":"A comparison of interactive immersive virtual reality and still nature pictures as distraction-based analgesia in burn wound care","volume":"49","author":"Patterson","year":"2023","journal-title":"Burns"},{"key":"2023050213312215700_CIT0006","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.burns.2021.10.012","article-title":"The effect of reflexology massage and passive music therapy intervention before burn dressing on pain, anxiety level and sleep quality","volume":"48","author":"Kabuk","year":"2022","journal-title":"Burns"},{"key":"2023050213312215700_CIT0007","doi-asserted-by":"crossref","first-page":"102758","DOI":"10.1016\/j.ctim.2021.102758","article-title":"Effectiveness of lavender inhalation aromatherapy on pain level and vital signs in children with burns: a randomized controlled trial","volume":"60","author":"Akg\u00fcl","year":"2021","journal-title":"Complement Ther Med"},{"key":"2023050213312215700_CIT0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.ASW.0000801544.79621.24","article-title":"The effect of inhalation aromatherapy on sedation level, analgesic dosage, and bispectral index values during donor site dressing in patients with burns: a randomized clinical trial","volume":"35","author":"Froutan","year":"2022","journal-title":"Adv Skin Wound Care"},{"key":"2023050213312215700_CIT0009","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1016\/j.burns.2017.04.025","article-title":"The use of acupuncture in first aid of burns-Clinical report","volume":"43","author":"Loskotova","year":"2017","journal-title":"Burns"},{"key":"2023050213312215700_CIT0010","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/jbcr\/irac159","article-title":"Efficacy of a novel LAM femoral cutaneous block technique for acute donor site pain","volume":"44","author":"Hill","year":"2023","journal-title":"J Burn Care Res"},{"key":"2023050213312215700_CIT0011","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.burns.2020.06.011","article-title":"Intraoperative liposomal bupivacaine for skin graft donor site analgesia: a retrospective cohort study","volume":"47","author":"Artz","year":"2021","journal-title":"Burns"},{"key":"2023050213312215700_CIT0012","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1177\/0897190019876497","article-title":"Oral administration of injectable ketamine during burn wound dressing changes","volume":"34","author":"Lintner","year":"2021","journal-title":"J Pharm Pract"},{"key":"2023050213312215700_CIT0013","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.burns.2019.07.031","article-title":"A prospective analysis describing the innovative use of liposomal bupivacaine in burn patients","volume":"46","author":"Boyd","year":"2020","journal-title":"Burns"},{"key":"2023050213312215700_CIT0014","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1016\/j.burns.2017.02.007","article-title":"Complex regional pain syndrome in burn pathological scarring: a case report and review of the literature","volume":"43","author":"Mewa Kinoo","year":"2017","journal-title":"Burns"},{"key":"2023050213312215700_CIT0015","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.bjps.2022.02.052","article-title":"Posttraumatic stress disorder in burn patient: a systematic review","volume":"75","author":"Paggiaro","year":"2022","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"2023050213312215700_CIT0016","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.cps.2017.02.026","article-title":"Sedation and pain management in burn patients","volume":"44","author":"Griggs","year":"2017","journal-title":"Clin Plast Surg"},{"key":"2023050213312215700_CIT0017","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1093\/jbcr\/irz111","article-title":"A review of adjunctive therapies for burn injury pain during the opioid crisis","volume":"40","author":"Kim","year":"2019","journal-title":"J Burn Care Res"},{"key":"2023050213312215700_CIT0018","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.burns.2019.03.028","article-title":"Drug-specific differences in the ability of opioids to manage burn pain","volume":"46","author":"Emery","year":"2020","journal-title":"Burns"},{"key":"2023050213312215700_CIT0019","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cps.2017.02.012","article-title":"Rational selection and use of antimicrobials in patients with burn injuries","volume":"44","author":"Hill","year":"2017","journal-title":"Clin Plast Surg"},{"key":"2023050213312215700_CIT0020","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2165\/00003088-200847100-00002","article-title":"Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients","volume":"47","author":"Blanchet","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"2023050213312215700_CIT0021","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/ALN.0000000000000559","article-title":"Acute and perioperative care of the burn-injured patient","volume":"122","author":"Bittner","year":"2015","journal-title":"Anesthesiology"},{"key":"2023050213312215700_CIT0022","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.burnso.2022.01.002","article-title":"Wound healing in older adults with severe burns: Clinical treatment considerations and challenges","volume":"6","author":"Romanowski","year":"2022","journal-title":"Burns Open"},{"key":"2023050213312215700_CIT0023","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1093\/jbcr\/irz115","article-title":"The influence of obesity on treatment and outcome of severely burned patients","volume":"40","author":"Tapking","year":"2019","journal-title":"J Burn Care Res"},{"key":"2023050213312215700_CIT0024","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/j.burns.2019.04.016","article-title":"Analysis of factors impacting length of stay in thermal and inhalation injury","volume":"45","author":"Smith","year":"2019","journal-title":"Burns"},{"key":"2023050213312215700_CIT0025","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/jbcr\/irac071","article-title":"A comprehensive, retrospective analysis of variables for potential mortality impact in patients with thermal or inhalation injury","volume":"44","author":"Buckley","year":"2023","journal-title":"J Burn Care Res"},{"key":"2023050213312215700_CIT0026","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/phar.1223","article-title":"Cost and quality implications of opioid-based postsurgical pain control using administrative claims data from a large health system: opioid-related adverse events and their impact on clinical and economic outcomes","volume":"33","author":"Kessler","year":"2013","journal-title":"Pharmacotherapy"},{"key":"2023050213312215700_CIT0027","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1001\/jamasurg.2018.1039","article-title":"Association of opioid-related adverse drug events with clinical and cost outcomes among surgical patients in a large integrated health care delivery system","volume":"153","author":"Shafi","year":"2018","journal-title":"JAMA Surg"},{"key":"2023050213312215700_CIT0028","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1476-9255-6-7","article-title":"Post heat shock tolerance: a neuroimmunological anti-inflammatory phenomenon","volume":"6","author":"Shahabi","year":"2009","journal-title":"J Inflamm (Lond)"},{"key":"2023050213312215700_CIT0029","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/pm\/pnx228","article-title":"Burn pain: a systematic and critical review of epidemiology, pathophysiology, and treatment","volume":"19","author":"Morgan","year":"2018","journal-title":"Pain Med"},{"key":"2023050213312215700_CIT0030","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.3390\/ijms21113880","article-title":"Post-burn pruritus","volume":"21","author":"Chung","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2023050213312215700_CIT0031","doi-asserted-by":"crossref","first-page":"e00789","DOI":"10.1002\/prp2.789","article-title":"Addressing opioid tolerance and opioid-induced hypersensitivity: Recent developments and future therapeutic strategies","volume":"9","author":"Khan","year":"2021","journal-title":"Pharmacol Res Perspect"},{"key":"2023050213312215700_CIT0032","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1124\/pr.112.007138","article-title":"Mu opioids and their receptors: evolution of a concept","volume":"65","author":"Pasternak","year":"2013","journal-title":"Pharmacol Rev"},{"key":"2023050213312215700_CIT0033","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.neuroscience.2005.06.003","article-title":"Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling","volume":"135","author":"Wang","year":"2005","journal-title":"Neuroscience"},{"key":"2023050213312215700_CIT0034","first-page":"859","article-title":"Buprenorphine - an attractive opioid with underutilized potential in treatment of chronic pain","volume":"8","author":"Khanna","year":"2015","journal-title":"J Pain Res"},{"key":"2023050213312215700_CIT0035","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/CJ9.0000000000000009","article-title":"Management of acute pain in extensive burn injury: nonsystematic review of the literature","volume":"46","author":"C\u00e1ceres-Jerez","year":"2018","journal-title":"Colombian J Anesthesiol"},{"key":"2023050213312215700_CIT0036","doi-asserted-by":"crossref","first-page":"821","DOI":"10.2147\/TCRM.S262843","article-title":"Safe use of opioids in chronic kidney disease and hemodialysis patients: tips and tricks for non-pain specialists","volume":"16","author":"Coluzzi","year":"2020","journal-title":"Ther Clin Risk Manag"},{"key":"2023050213312215700_CIT0037","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4062\/biomolther.2016.165","article-title":"Biased G protein-coupled receptor signaling: new player in modulating physiology and pathology","volume":"25","author":"Bologna","year":"2017","journal-title":"Biomol Ther (Seoul)"},{"key":"2023050213312215700_CIT0038","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1213\/01.ANE.0000160588.32007.AD","article-title":"The role of opioid receptor internalization and beta-arrestins in the development of opioid tolerance","volume":"101","author":"Zuo","year":"2005","journal-title":"Anesth Analg"},{"key":"2023050213312215700_CIT0039","doi-asserted-by":"crossref","first-page":"7847","DOI":"10.1523\/JNEUROSCI.5045-04.2005","article-title":"Morphine promotes rapid, arrestin-dependent endocytosis of mu-opioid receptors in striatal neurons","volume":"25","author":"Haberstock-Debic","year":"2005","journal-title":"J Neurosci"},{"key":"2023050213312215700_CIT0040","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/jnr.24695","article-title":"Pain management with opioids in adults","volume":"100","author":"Montgomery","year":"2022","journal-title":"J Neurosci Res"},{"key":"2023050213312215700_CIT0041","volume-title":"Pain management and the Opioid epidemic: balancing societal and individual benefits and risks of prescription Opioid use","author":"National Academies of Sciences, Engineering, and Medicine; Health and Medicvine Division; Board on Health Sciences Policy; Committee on Pain Management and Regulatory Strategies to Address Prescription Opioid Abuse","year":"2017"},{"key":"2023050213312215700_CIT0042","volume-title":"Federal regulation of methadone treatment","author":"Rettig","year":"1995"},{"key":"2023050213312215700_CIT0043","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/2049463712438493","article-title":"Basic opioid pharmacology: an update","volume":"6","author":"Pathan","year":"2012","journal-title":"Br J Pain"},{"key":"2023050213312215700_CIT0044","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.3389\/fphar.2018.01388","article-title":"Advances in achieving opioid analgesia without side effects","volume":"9","author":"Machelska","year":"2018","journal-title":"Front Pharmacol"},{"key":"2023050213312215700_CIT0045","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/bjaceaccp\/mki004","article-title":"Opioid receptors","volume":"5","author":"McDonald","year":"2005","journal-title":"Continuing Educ Anaesthesia Crit Care Pain"},{"key":"2023050213312215700_CIT0046","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.36076\/ppj.2008\/11\/S133","article-title":"Opioid pharmacology","volume":"11","author":"Trescot","year":"2008","journal-title":"Pain Physician"},{"key":"2023050213312215700_CIT0047","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.tips.2011.06.008","article-title":"The delta opioid receptor: an evolving target for the treatment of brain disorders","volume":"32","author":"Pradhan","year":"2011","journal-title":"Trends Pharmacol Sci"},{"key":"2023050213312215700_CIT0048","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/164_2016_116","article-title":"Insights into the role of opioid receptors in the GI tract: experimental evidence and therapeutic relevance","volume":"239","author":"Galligan","year":"2017","journal-title":"Handb Exp Pharmacol"},{"key":"2023050213312215700_CIT0049","doi-asserted-by":"crossref","first-page":"R1599","DOI":"10.1152\/ajpregu.00020.2008","article-title":"Inhibitory and excitatory effects of micro-, delta-, and kappa-opioid receptor activation on breathing in awake turtles, Trachemys scripta","volume":"295","author":"Johnson","year":"2008","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"2023050213312215700_CIT0050","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1124\/jpet.112.201616","article-title":"A G protein-biased ligand at the mu-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine","volume":"344","author":"DeWire","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"2023050213312215700_CIT0051","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/0024-3205(95)00010-4","article-title":"Affinity profiles of morphine, codeine, dihydrocodeine and their glucuronides at opioid receptor subtypes","volume":"56","author":"Mignat","year":"1995","journal-title":"Life Sci"},{"key":"2023050213312215700_CIT0052","doi-asserted-by":"crossref","first-page":"113986","DOI":"10.1016\/j.ejmech.2021.113986","article-title":"Synthesis, biological, and structural explorations of a series of \u03bc-opioid receptor (MOR) agonists with high G protein signaling bias","volume":"228","author":"Yang","year":"2022","journal-title":"Eur J Med Chem"},{"key":"2023050213312215700_CIT0053","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/j.1476-5381.2012.02075.x","article-title":"Ligand-directed signalling within the opioid receptor family","volume":"167","author":"Pradhan","year":"2012","journal-title":"Br J Pharmacol"},{"key":"2023050213312215700_CIT0054","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/jbcr\/iry053","article-title":"Identification of cytochrome P450 polymorphisms in burn patients and impact on fentanyl pharmacokinetics: a pilot study","volume":"40","author":"Grimsrud","year":"2019","journal-title":"J Burn Care Res"},{"key":"2023050213312215700_CIT0055","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/jbcr\/irac062","article-title":"Pharmacogenetic gene-drug associations in pediatric burn and surgery patients","volume":"43","author":"Grimsrud","year":"2022","journal-title":"J Burn Care Res"},{"key":"2023050213312215700_CIT0056","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/bcpt.13141","article-title":"Polymorphisms associated with fentanyl pharmacokinetics, pharmacodynamics and adverse effects","volume":"124","author":"Saiz-Rodr\u00edguez","year":"2019","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2023050213312215700_CIT0057","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/bja\/aeu186","article-title":"Morphine-6-glucuronide is responsible for the analgesic effect after morphine administration: a quantitative review of morphine, morphine-6-glucuronide, and morphine-3-glucuronide","volume":"113","author":"Klimas","year":"2014","journal-title":"Br J Anaesth"},{"key":"2023050213312215700_CIT0058","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3389\/fncel.2014.00349","article-title":"The UDP-glucuronosyltransferases of the blood-brain barrier: their role in drug metabolism and detoxication","volume":"8","author":"Ouzzine","year":"2014","journal-title":"Front Cell Neurosci"},{"key":"2023050213312215700_CIT0059","doi-asserted-by":"crossref","first-page":"882443","DOI":"10.3389\/fnmol.2022.882443","article-title":"Morphine-3-glucuronide, physiology and behavior","volume":"15","author":"Gabel","year":"2022","journal-title":"Front Mol Neurosci"},{"key":"2023050213312215700_CIT0060","doi-asserted-by":"crossref","first-page":"10S10","DOI":"10.1016\/j.jpainsymman.2005.01.004","article-title":"Opioid metabolites","volume":"29","author":"Lotsch","year":"2005","journal-title":"J Pain Symptom Manage"},{"key":"2023050213312215700_CIT0061","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0025-6196(11)60750-7","article-title":"Opioid metabolism","volume":"84","author":"Smith","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"2023050213312215700_CIT0062","doi-asserted-by":"crossref","first-page":"114293","DOI":"10.1016\/j.bcp.2020.114293","article-title":"Affinity, potency, efficacy, selectivity, and molecular modeling of substituted fentanyls at opioid receptors","volume":"182","author":"Eshleman","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"2023050213312215700_CIT0063","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1111\/bph.13809","article-title":"Targeting multiple opioid receptors - improved analgesics with reduced side effects?","volume":"175","author":"G\u00fcnther","year":"2018","journal-title":"Br J Pharmacol"},{"key":"2023050213312215700_CIT0064","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1016\/0006-2952(89)90001-4","article-title":"The new biology of drug receptors","volume":"38","author":"Lefkowitz","year":"1989","journal-title":"Biochem Pharmacol"},{"key":"2023050213312215700_CIT0065","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0968-0004(92)90425-9","article-title":"From ligand binding to gene expression: new insights into the regulation of G-protein-coupled receptors","volume":"17","author":"Collins","year":"1992","journal-title":"Trends Biochem Sci"},{"key":"2023050213312215700_CIT0066","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nrd.2017.229","article-title":"Biased signalling: from simple switches to allosteric microprocessors","volume":"17","author":"Smith","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"2023050213312215700_CIT0067","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1126\/science.aaw8981","article-title":"Mechanism of \u03b2(2)AR regulation by an intracellular positive allosteric modulator","volume":"364","author":"Liu","year":"2019","journal-title":"Science"},{"key":"2023050213312215700_CIT0068","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nature12120","article-title":"Structure of active \u03b2-arrestin-1 bound to a G-protein-coupled receptor phosphopeptide","volume":"497","author":"Shukla","year":"2013","journal-title":"Nature"},{"key":"2023050213312215700_CIT0069","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/nature13430","article-title":"Visualization of arrestin recruitment by a G-protein-coupled receptor","volume":"512","author":"Shukla","year":"2014","journal-title":"Nature"},{"key":"2023050213312215700_CIT0070","first-page":"489308","article-title":"Biased ligands at G-protein-coupled receptors: promise and progress","volume":"35","author":"Violin","year":"2014","journal-title":"Trends Pharmacol Sci"},{"key":"2023050213312215700_CIT0071","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3389\/fphar.2019.00125","article-title":"GPCR signaling regulation: the role of GRKs and arrestins","volume":"10","author":"Gurevich","year":"2019","journal-title":"Front Pharmacol"},{"key":"2023050213312215700_CIT0072","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1124\/jpet.105.087254","article-title":"Morphine side effects in beta-arrestin 2 knockout mice","volume":"314","author":"Raehal","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"2023050213312215700_CIT0073","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1126\/science.286.5449.2495","article-title":"Enhanced morphine analgesia in mice lacking beta-arrestin 2","volume":"286","author":"Bohn","year":"1999","journal-title":"Science"},{"key":"2023050213312215700_CIT0074","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1124\/jpet.119.258640","article-title":"A novel G protein-biased agonist at the \u03b4 opioid receptor with analgesic efficacy in models of chronic pain","volume":"372","author":"Conibear","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"key":"2023050213312215700_CIT0075","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1213\/ANE.0000000000005309","article-title":"Potential for kappa-opioid receptor agonists to engineer nonaddictive analgesics: a narrative review","volume":"132","author":"Kaski","year":"2021","journal-title":"Anesth Analg"},{"key":"2023050213312215700_CIT0076","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1213\/ANE.0000000000003662","article-title":"Pharmacological characters of oliceridine, a mu-opioid receptor G-protein-biased ligand in mice","volume":"129","author":"Liang","year":"2019","journal-title":"Anesth Analg"},{"key":"2023050213312215700_CIT0077","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1177\/0269881116689257","article-title":"Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents","volume":"31","author":"Altarifi","year":"2017","journal-title":"J Psychopharmacol"},{"key":"2023050213312215700_CIT0078","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scisignal.aaz3140","article-title":"Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists","volume":"13","author":"Gillis","year":"2020","journal-title":"Sci Signal"},{"key":"2023050213312215700_CIT0079","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1021\/acs.biochem.1c00466","article-title":"Low intrinsic efficacy alone cannot explain the improved side effect profiles of new opioid agonists","volume":"61","author":"Stahl","year":"2022","journal-title":"Biochemistry"},{"key":"2023050213312215700_CIT0080","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1358\/dot.2020.56.4.3107707","article-title":"Oliceridine, a G protein-selective ligand at the \u03bc-opioid receptor, for the management of moderate to severe acute pain","volume":"56","author":"Gan","year":"2020","journal-title":"Drugs Today (Barc)"},{"key":"2023050213312215700_CIT0081","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/cpdd.750","article-title":"The influence of renal or hepatic impairment on the pharmacokinetics, safety, and tolerability of oliceridine","volume":"9","author":"Nafziger","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2023050213312215700_CIT0082","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/jcph.207","article-title":"First clinical experience with TRV130: pharmacokinetics and pharmacodynamics in healthy volunteers","volume":"54","author":"Soergel","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"2023050213312215700_CIT0083","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/j.pain.2014.06.011","article-title":"Biased agonism of the mu-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: a randomized, double-blind, placebo-controlled, crossover study in healthy volunteers","volume":"155","author":"Soergel","year":"2014","journal-title":"Pain"},{"key":"2023050213312215700_CIT0084","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/j.pain.0000000000000363","article-title":"A randomized, phase 2 study investigating TRV130, a biased ligand of the mu-opioid receptor, for the intravenous treatment of acute pain","volume":"157","author":"Viscusi","year":"2016","journal-title":"Pain"},{"key":"2023050213312215700_CIT0085","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.2147\/JPR.S137952","article-title":"A randomized, Phase IIb study investigating oliceridine (TRV130), a novel micro-receptor G-protein pathway selective (mu-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty","volume":"10","author":"Singla","year":"2017","journal-title":"J Pain Res"},{"key":"2023050213312215700_CIT0086","doi-asserted-by":"crossref","first-page":"927","DOI":"10.2147\/JPR.S171013","article-title":"APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the micro-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy","volume":"12","author":"Viscusi","year":"2019","journal-title":"J Pain Res"},{"key":"2023050213312215700_CIT0087","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/papr.12801","article-title":"APOLLO-2: a randomized, placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the mu-opioid receptor, for management of moderate to severe acute pain following abdominoplasty","volume":"19","author":"Singla","year":"2019","journal-title":"Pain Pract"},{"key":"2023050213312215700_CIT0088","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.2147\/JPR.S217563","article-title":"ATHENA: a Phase 3, open-label study of the safety and effectiveness of oliceridine (TRV130), a G-protein selective agonist at the \u00b5-opioid receptor, in patients with moderate to severe acute pain requiring parenteral opioid therapy","volume":"12","author":"Bergese","year":"2019","journal-title":"J Pain Res"},{"key":"2023050213312215700_CIT0089","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s40122-020-00216-x","article-title":"Oliceridine is associated with reduced risk of vomiting and need for rescue antiemetics compared to morphine: exploratory analysis from two phase 3 randomized placebo and active controlled trials","volume":"10","author":"Beard","year":"2020","journal-title":"Pain Ther"},{"key":"2023050213312215700_CIT0090","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s40122-020-00232-x","article-title":"Low incidence of opioid-induced respiratory depression observed with oliceridine regardless of age or body mass index: exploratory analysis from a phase 3 open-label trial in postsurgical pain","volume":"10","author":"Brzezinski","year":"2021","journal-title":"Pain Ther"}],"container-title":["Journal of Burn Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbcr\/advance-article-pdf\/doi\/10.1093\/jbcr\/irad004\/49190781\/irad004.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbcr\/article-pdf\/44\/3\/524\/50169175\/irad004.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbcr\/article-pdf\/44\/3\/524\/50169175\/irad004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T13:35:33Z","timestamp":1683034533000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbcr\/article\/44\/3\/524\/6987178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":90,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,1,13]]},"published-print":{"date-parts":[[2023,5,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jbcr\/irad004","relation":{},"ISSN":["1559-047X","1559-0488"],"issn-type":[{"value":"1559-047X","type":"print"},{"value":"1559-0488","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5,1]]},"published":{"date-parts":[[2023,1,13]]}}}